MX2010005057A - Metodos y composiciones para uso de diagnostico en pacientes de cancer. - Google Patents

Metodos y composiciones para uso de diagnostico en pacientes de cancer.

Info

Publication number
MX2010005057A
MX2010005057A MX2010005057A MX2010005057A MX2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cancer patients
diagnostic use
cancer
Prior art date
Application number
MX2010005057A
Other languages
English (en)
Spanish (es)
Inventor
Thomas D Wu
Daniel S Chen
Couter Jennifer Le
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010005057A publication Critical patent/MX2010005057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
MX2010005057A 2007-11-09 2008-11-05 Metodos y composiciones para uso de diagnostico en pacientes de cancer. MX2010005057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
MX2010005057A true MX2010005057A (es) 2010-05-19

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005057A MX2010005057A (es) 2007-11-09 2008-11-05 Metodos y composiciones para uso de diagnostico en pacientes de cancer.

Country Status (13)

Country Link
US (2) US20090123930A1 (https=)
EP (1) EP2222874A2 (https=)
JP (1) JP2011502513A (https=)
KR (1) KR20100095571A (https=)
CN (1) CN101910416A (https=)
AU (1) AU2008324782A1 (https=)
BR (1) BRPI0817158A2 (https=)
CA (1) CA2703258A1 (https=)
IL (1) IL205246A0 (https=)
MX (1) MX2010005057A (https=)
RU (1) RU2010123381A (https=)
WO (1) WO2009061800A2 (https=)
ZA (1) ZA201002808B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482715A (zh) * 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
AU2010297344A1 (en) * 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
EP2848939A1 (en) * 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CA2804246A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
RU2015102026A (ru) * 2012-06-26 2016-08-10 Ф.Хоффманн-Ля Рош Аг Биомаркеры в плазме крови для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
MX2015006955A (es) * 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
TW202528738A (zh) * 2023-11-09 2025-07-16 昇捷生物科技股份有限公司 基於α-1抗胰蛋白酶生物標記物之癌症檢測方法及套組

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
CA2604549A1 (en) * 2005-04-13 2006-10-19 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
WO2007123722A2 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
EP2222874A2 (en) 2010-09-01
US20090123930A1 (en) 2009-05-14
CN101910416A (zh) 2010-12-08
WO2009061800A2 (en) 2009-05-14
RU2010123381A (ru) 2011-12-20
IL205246A0 (en) 2010-12-30
ZA201002808B (en) 2011-07-27
US20110151468A1 (en) 2011-06-23
JP2011502513A (ja) 2011-01-27
BRPI0817158A2 (pt) 2015-04-14
AU2008324782A1 (en) 2009-05-14
CA2703258A1 (en) 2009-05-14
WO2009061800A3 (en) 2009-07-16
KR20100095571A (ko) 2010-08-31

Similar Documents

Publication Publication Date Title
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
PT3130923T (pt) Métodos terapêuticos relacionados com células estaminais
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
GB0708761D0 (en) Improvements in and relating to medical instruments
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MY160041A (en) Compositions and methods for treating parasitic infections
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
IL206748A (en) Molecular test for @cancer @ breast cancer @
PT2282758T (pt) Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
EP2614375A4 (en) COMBINATION METHOD FOR CANCER DIAGNOSIS
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2010054377A3 (en) Fully human antibodies against n-cadherin
MX2013003599A (es) Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
HUE031337T2 (hu) Opioidok rezisztens rákos betegek kezelésében történõ alkalmazásra
IL217209A0 (en) Novel antibodies and their uses in therapeutic and diagnostic methods
GB2465907A (en) VHZ for diagnosis and treatment of cancer
EP2115127A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING CELL HEALTH IN CULTURES
UA95956C2 (uk) Набір для визначення mage-а3
HK1142372A (en) Methods and compositions for diagnostic use in cancer patients

Legal Events

Date Code Title Description
FA Abandonment or withdrawal